After 140 billion immune cells entered her body, all seven of her tumors went into remission

Genetic mutations are often considered to be the root cause of cancer.

For example, KRAS mutations, which are so stubborn that few drugs can take them down, are found in about 22% of cancer patients, especially pancreatic cancer (68%), cholangiocarcinoma (27%) and lung cancer (17%)...

Finding a way to suppress this difficult KRAS mutation could lead to treatment for these patients.

A new immunotherapy therapy published in the New England Journal of Medicine has shocked the oncology world.

This therapy has become the most promising tumor immunotherapy with its amazing clinical data, and also thanks to its excellent clinical efficacy, Celine Ryan, who is nearly 50 years old, started a new life. After the treatment of the new therapy, Ryan almost came back from the dead, and all the 7 metastatic lesions in his body disappeared!

The new immunotherapy rekindled her hope of life

In 2013, Ryan was diagnosed with advanced colorectal cancer at the age of nearly 50. She had hoped to be cured with surgery to remove the tumor and chemotherapy to kill the remaining cancer cells, but she had clearly underestimated the power of cancer.

Surgery and chemotherapy did help, but soon the cancer had spread to both lungs, to about ten large and small metastases, and she was declared to have a very poor survival. There was nothing better to do than continue chemotherapy.

But for the sake of her five children, she was determined to beat cancer.

After searching the Internet for more treatments, Ryan finally found hope.

She had read online reports about Ms. Bachini, a 43-year-old mother of six who, like Ryan, had decided that chemotherapy would not save her, a patient diagnosed with deadly cholangiocarcinoma, whose tumor had spread despite surgery and repeated painful chemotherapy treatments, and who had just months to live. So she found the latest immunotherapy clinical trial being conducted by Dr. Steven A. Rosenberg of the National Cancer Institute, and miraculously, after the treatment, Ms. Bachini's tumors were gone.

This gave Ryan renewed hope when she learned that Professor Rosenberg's ongoing immunotherapy clinical study, called TILs (Tumor-infiltrating Lymphocyte), had published data that demonstrated lasting complete regression in 20-25% of patients with metastatic melanoma.

So Ryan decided to try the new treatment and applied for a clinical trial.

2.14 billion immune cells enter the body, and the tumor fights them off

Soon, Ryan was admitted to the group and was lucky enough to meet Professor Rosenberg, director of surgery at the American Institute of Cancer Research.

Professor Rosenberg performed the surgery on Ryan, extracting tumor-infiltrating lymphocytes (TIL) from tumor tissue removed from her lung lesions, and then isolating and amplifying different types of T cells in a specialized GMP facility.

Meanwhile, in the gene sequencing analysis of tumor tissue, Professor Rosenberg found a large number of KRAS G12D mutations in Ryan's tumor tissue.

Thruugh further screening and extraction of CD8 + T cells that can specifically recognize the mutation of KRAS G12D, these cells are the most powerful immune cells that can accurately kill Ryan's tumor cells. The researchers then amplified and cultured these precious cells to 148 billion.

After starting a week of preconditioning chemotherapy, Ryan was finally born again.

148 billion tumor-infiltrating lymphocytes that specifically recognized KRAS G12D flooded back into Ryan and began clearing away cancer cells. Ryan also received interleukin 2 (IL-2) to support the growth and activation of immune cells in his body.

Only 40 days later, Ryan's first review was surprised to find that all the remaining 7 metastatic lesions on the lung had subsided, and three of them had completely disappeared! Even doctors are calling it another miracle of the new immunotherapy.

To date, the American Institute for Cancer Research has treated 12 patients with metastatic GASTROINTESTINAL cancer with TIL targeting various tumor antigens, and more patients are expected to benefit in the future.

What was the therapy that gave her a new lease of life?

So what is this amazing TIL therapy? Why does it work so well?

Cancer is known to result from mutations in healthy cells in the body. As a result, the body's T cells, which are specifically responsible for killing tumors, sometimes fail to recognize cancer cells as "face-blind," which prevents them from killing tumors accurately and effectively.

Finding immune T cells that can kill enemies with precision is particularly important.

TIL is a group of specialized immune cells, called tumor-infiltrating lymphocytes, that cluster around a tumor. They penetrate into tumor tissue and are able to recognize and kill tumor cells with precision.

However, TIL was too few to cope with the rapid growth of tumor tissue, so in vitro amplification and delivery back to the patient to fight the tumor became the most effective method scientists could think of, and TIL immunotherapy was developed.

Although it does not have the same reputation as CAR-T or PD-1, TIL immunotherapy is also very promising in solid tumors. Although the new immunotherapy is not yet on the market, there are several clinical trials in various solid tumors worldwide.

TIL therapy lN-145 has been granted breakthrough therapy designation by the FDA. This is the first time that a cellular immunotherapy for solid tumors has been granted breakthrough therapy designation. It is believed that it is only a matter of time before immunotherapy is available on the market.